TICKERNERD
Menu
INBXINBXHealthcare · Biotechnology

INBX Stock Forecast: Inhibrx Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$109
−2.04% on the day

The 4 Wall Street analysts covering Inhibrx Biosciences, Inc. hold a median 12-month price target of $245 — +124.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
27 / 100
Median analyst target
$245
Analysts covering
4
Revenue$0.0−100.0% y/y
Operating income−$32.1M
Net income−$36.6M
Free cash flow−$29.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.7%
1M
+18.1%
YTD
+38.2%
1Y
+283.6%
From 52W high
−23.1%
From 52W low
+311.3%
$27
$142
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INBX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inhibrx Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Accruals
66
Growth
54
Value
47
Size
39
Revisions
31
Issuance
18
Volatility
14
Quality
9

Momentum (90): The shares have been drifting up relative to others.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INBX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INBX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200$250$300$350Oct 25Jan 26Apr 26Jul 26INBXHigh $325Median $245Low $230

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $230Median $245High $325

The green dot is the last close — the median target sits +124.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026HC Wainwright & Co.InitiatesBuy$245
8 Apr 2026StifelInitiatesBuy$150
8 Apr 2026StifelInitiatesBuy—
22 Aug 2025JMP SecuritiesReiteratesMarket Perform—
15 May 2025JMP SecuritiesReiteratesMarket Perform—
18 Mar 2025Citizens Capital MarketsReiteratesMarket Perform—
22 Jan 2025JMP SecuritiesReiteratesMarket Perform—
23 July 2024JMP SecuritiesInitiatesMarket Perform—
23 Jan 2024JMP SecuritiesDowngradeMarket Perform—
20 Nov 2023JMP SecuritiesReiteratesMarket Outperform—
23 Aug 2023JMP SecuritiesMaintainsOutperform—
10 May 2023JMP SecuritiesReiteratesMarket Outperform—
8 Mar 2023JMP SecuritiesMaintainsMarket Outperform—
7 Mar 2023Credit SuisseReiteratesOutperform—
8 Nov 2022Credit SuisseMaintainsOutperform—
5 Oct 2022Evercore ISI GroupMaintainsOutperform—
25 Aug 2022SMBC NikkoInitiatesOutperform—
9 Aug 2022Credit SuisseMaintainsOutperform—
16 Mar 2022SMBC NikkoInitiatesOutperform—
2 Mar 2022JMP SecuritiesMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INBX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INBX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Inhibrx Biosciences, Inc. returned +283.6% against +17.5% for the S&P 500, dividends included.

INBX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26INBXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INBX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Inhibrx Biosciences, Inc. (INBX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
1235.7×

Cheaper than 1% of US stocks

Price / book
−32.2×

Cheaper than 99% of US stocks

EV / EBITDA
−13.2×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−9835.2%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1773.6%

Higher than 1% of US stocks

Return on assets
−43.6%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Inhibrx Biosciences, Inc. (INBX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inhibrx Biosciences, Inc. has a market value of $1.6B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$138.2M.

  • Diluted earnings per share, trailing twelve months: $−8.88.

  • Free cash flow in the twelve months to 30 June 2026: −$131.9M.

  • Shares outstanding: 14.7M.

  • Trailing P/E: 0.2×; forward P/E: −12.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Inhibrx Biosciences, Inc. employs 109 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

INBX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INBXInhibrx Biosciences, Inc.$1.6B
27
TSHATaysha Gene Therapies, Inc.$1.6B
42
ANABAnaptysBio, Inc.$1.6B
99
SNDXSyndax Pharmaceuticals, Inc.$1.6B
61
FTREFortrea Holdings, Inc.$1.6B
97
FBRXForte Biosciences, Inc.$1.6B
—
NTLAIntellia Therapeutics, Inc.$1.6B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inhibrx Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INBX news & analysis

Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom

Seeking Alpha · 9 Sept 2026positive

Inhibrx reported data for INBRX-106 combined with Keytruda showing a 48.3% confirmed overall response rate in head and neck cancer, with pronounced efficacy in HPV+ patients, though the market response remained muted. The company also advances ozekibart, which showed a 52% risk reduction in chondrosarcoma progression, with an FDA BLA decision due by April 2027.

Why it matters — INBX watchers would care because the positive clinical data for INBRX-106 and ozekibart could support the company's pipeline value and future regulatory milestones.

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Benzinga · 8 Sept 2026positive

Inhibrx Biosciences announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study, reporting high response rates. The company plans to expand its head and neck cancer trial based on these findings.

Why it matters — A watcher of INBX would be interested because these Phase 2 results and the planned trial expansion could signal progress for the company's head and neck cancer program.

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study

Reuters · 8 Sept 2026positive

Inhibrx Biosciences announced that its experimental combination cancer drug reduced tumors in a mid-stage study involving patients with a type of head and neck cancer. The results come from a mid-stage trial.

Why it matters — This is an early efficacy signal for Inhibrx's lead experimental drug in a common cancer type, which watchers would view as a meaningful step for the company's pipeline.

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

PRNewsWire · 8 Sept 2026positive

Inhibrx reported primary endpoint results from the Phase 2 HexAgon study, showing that INBRX-106 (a hexavalent OX40 agonist) in combination with pembrolizumab achieved a 48.3% confirmed overall response rate versus 26.5% for pembrolizumab alone, with 72.4% of patients progression-free at 6 months compared to 42.8%. The company plans to expand the study by approximately 50 HPV+ patients, which may serve as a potential pathway to accelerated approval.

Why it matters — The data, described as the first OX40 agonist to demonstrate clinical benefit in a randomized study, could support INBRX-106's development path and potential expansion into other indications for Inhibrx.

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

PRNewsWire · 4 Sept 2026neutral

Inhibrx announced it will host a webcast presentation on Tuesday, September 8th at 5:00 a.m. PT to provide primary endpoint results from its INBRX-106 Phase 2 first-line head and neck squamous cell carcinoma (HNSCC) study. The event will be broadcast live.

Why it matters — The webcast will deliver primary endpoint results from a key Phase 2 INBRX-106 study, which INBX watchers would want to see.

FAQ

Frequently asked questions about INBX stock

What is the INBX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Inhibrx Biosciences, Inc. have a median 12-month price target of $245, with estimates ranging from $230 to $325. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INBX stock a buy right now?

Of the 4 analysts covering Inhibrx Biosciences, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inhibrx Biosciences, Inc. 27 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INBX?

As at 12 Sept 2026, Inhibrx Biosciences, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will INBX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +124.5% from the last close, and Ticker Nerd's factor model ranks Inhibrx Biosciences, Inc. 27 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INBX stock forecast for 2030?

No analyst covering Inhibrx Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $325 over the next 12 months.

How has INBX stock performed over the past year?

Inhibrx Biosciences, Inc. returned +283.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inhibrx Biosciences, Inc. do?

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered biologic therapies for oncology and other serious diseases.

What is the latest news on INBX?

The most recent item we track (Seeking Alpha, 9 Sept 2026): "Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom". Inhibrx reported data for INBRX-106 combined with Keytruda showing a 48.3% confirmed overall response rate in head and neck cancer, with pronounced efficacy in HPV+ patients, though the market response remained muted. The company also advances ozekibart, which showed a 52% risk reduction in chondrosarcoma progression, with an FDA BLA decision due by April 2027.

Company

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered biologic therapies for oncology and other serious diseases. Inhibrx Biosciences uses proprietary protein engineering platforms to design multivalent therapeutic candidates that are intended to interact precisely with complex biological targets. Its current pipeline centers on ozekibart (INBRX-109) and INBRX-106, programs being advanced in clinical studies across solid tumors and rare cancer settings. The company’s work is directed toward creating targeted medicines that address difficult-to-treat conditions through differentiated biologic mechanisms. Headquartered in La Jolla, California, Inhibrx Biosciences plays a specialized role in the biopharmaceutical market as a developer of precision protein-based therapeutics.

CEO Mr. Mark Paul Lappe · 109 employees · United States · https://inhibrx.com